| Today’s Big NewsNov 14, 2023 |
| By Fraiser Kansteiner Pfizer plans to cut approximately 500 roles and ax its Pharmaceutical Sciences Small Molecule capabilities at its site in Sandwich in Kent in the U.K. The move is a consequence of Pfizer’s enterprisewide cost realignment program, which the drugmaker unveiled in mid-October. |
|
|
|
By Max Bayer Developing a functional cure for hepatitis B has proved elusive, with the pipeline of new clinical therapies incrementally growing in the last seven years. More midstage readouts and a handful of new deals are adding much-needed optimism that progress is being made. |
By Andrea Park Unfortunately for Vicarious Surgical, the robotic surgery system developer is ending the year the same way it began: with a round of layoffs. |
By Nick Paul Taylor GSK spinout Autifony Therapeutics has drummed up a collaboration with Jazz Pharmaceuticals, securing up to $770.5 million to discover and develop drug candidates against two ion channel targets associated with neurological disorders. |
By Kevin Dunleavy Add another to the list of healthcare companies joining Boston's transformed Seaport district, as Merck KGaA's pharma subsidiary, EMD Serono, said it will move its U.S. headquarters from 25 miles south in Rockland to Seaport. |
By Angus Liu One study in AstraZeneca’s elaborate R&D plan for lung cancer has reached a dead end. Failure of the Imfinzi-concurrent-chemoradiotherapy regimen deals a blow to AZ’s goal to target more than half of lung cancer patients by 2030. |
By Andrea Park Just a few months after the official U.S. launch of its Sensora platform, Eko Health has published a study detailing the real-world performance of the platform’s first artificial intelligence-powered heart disease detection tool. |
By James Waldron Telix Pharmaceuticals has offered to pay $33.1 million for Qsam Biosciences so the Australian biotech can get its hands on a phase 1 radiopharmaceutical for bone cancer. |
By Kevin Dunleavy In the clinic, Dermavant’s Vtama is progressing nicely as trial results have paved the way for it to be approved for atopic dermatitis (eczema) on top of its current indication for plaque psoriasis. In the market, however, Vtama is struggling to catch on. As a result, Leerink Partners has slashed its sales projections for the nonsteroidal topical treatment. |
Fierce podcastsDon’t miss an episode |
| In this episode of “The Top Line,” we explore the next potential wave of mental health therapy: psychedelics. |
|
|---|
|
|
|
Tuesday, November 28, 2023 | 11am ET / 8am PT Elevate your biopharmaceutical game! Join our webinar to explore game-changing solutions. Uncover the power of Recombumin® rHA – the consistent, animal-free alternative revolutionizing manufacturing. Don't miss this chance to stay ahead in the advanced therapy landscape.
|
|
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| WebinarWatch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| |
|
